UCB (OTC:UCBJF) Stock, Quote.Headers.trade-ideas

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Biogen,World,Headquarters,At,225,Binney,St.,In,Cambridge,,Ma,

Biotech

Large Cap

News

Health Care

General

BIIB

UCBJF

UCBJY

UCB and Biogen&#39;s lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results

Johnson & Johnson Inc. JNJ

PTGX

Protagonist and J&amp;J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Protagonist/Johnson &amp; Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

Analyst Color

Government

Analyst Ratings

Movers

Trading Ideas

ARGX

GILD

REGN

RHHBY

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

UCB SA

Comments

UCB

UCB (OTC:UCBJF) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell